Loading the records…
Loading the records…
Indian Health Service · INDIAN HEALTH SERVICE
Indian Health Service is planning to buy "NOI to Sole Source - Cepheid GeneXpert In-Vitro Diagnostic Test Kits and Reagents". This is an early notice: it is not taking bids yet. The work is in Kayenta, AZ, USA. Responses are due Dec 4, 2026. In the last 2 years, similar work went to 3 companies, usually for about $80K per award. An award is expected between January 2027 and April 2027.
Put together from the facts on this page; the details and sources are below.
Your briefs and their views: My briefs.
Every notice posted under solicitation IHS-2027-00092 in this department, oldest first.
Standard steps for the notice type; not advice about this buyer.
tion or a request for offers. Any potential sources other than Cepheid may submit a capability statement via electronic mail to Mr. Brandon Martinez, Contract Specialist, at Brandon.Martinez@ihs.gov by 11:00 am (MDT) on December 4, 2026. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. Oral communications are not acceptable in response to this notice. A determination by the Government not to complete the proposed procurement based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. A solicitation will not be issued.
4 award notices on SAM.gov in the last 24 months. Matched by: Same agency (Indian Health Service), same product/service code (PSC) 6550.
Single-winner award sizes (4): middle half $65K to $114K, median $80K; range $22K to $215K.
| Winner | Awards | Value | Last |
|---|---|---|---|
| ORTHO-CLINICAL DIAGNOSTICS, INC · $QDEL · $2.6B | 2 | $160K | May 28, 2025 |
| GOVERNMENT SCIENTIFIC SOURCE INC | 1 | $215K | Sep 11, 2026 |
| ABBOTT LABORATORIES INC. · $ABT · $48.2B | 1 | $22K | Jan 8, 2025 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
One award's total value against one year of revenue; many awards are paid over several years.
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
None of these past winners filed lobbying reports naming Indian Health Service since 2024. No sign of an incumbent lobbying push at this agency.
No lobbyist on these filings lists a past Indian Health Service job: no revolving-door tie found in these filings. (These are lobbyists the companies pay, not their own staff.)
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
No bills named on these filings under Indian Health Service-related issues.
A bill's title is shown only when the filing's own text names it; filings often cite last Congress's bill numbers.
No executive order in the last 12 months names Indian Health Service in its title or summary.
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.